KEYNOTE

"Korea achieved remarkable outcomes on the development of new formulation and manufacturing in therapeutics and vaccines and gained a competitive edge in the global market. Korea’s technological strength can play a key role in removing public health challenges in developing countries."
Dr. Paul Herrling, Chairman of the Selection Committee, RIGHT Fund & former vice president of the board of the Swiss Federal Institutes of Technology, at an interview with Korea Biomedical Review in April 2020.

"When Korea’s strengths in life science technology are applied to meeting the needs of developing countries, it will lead to a significant improvement of global public health."
Dr. Andrin Oswald, former Director of the Bill and Melinda Gates Foundation, during an interview with Yak-up newspaper in November 2019.

“A global public-private partnership, like the RIGHT Fund, must be further expanded and strengthened to promote health equity.”
Younbeen Kim, CEO of the RIGHT Fund, at Developing Countries Vaccine Manufactures Network Annual meeting in October 2019
In anticipation of the role of Korean strengths in improving global health

Technological advancements are bringing about astonishing worldwide changes every day. Diseases that have long caused tremendous misery are coming under control thanks to developments in bioscience and biotechnology. However, such benefits are not yet evenly distributed to all of humanity. Many elements of healthcare technology that we now take for granted are not yet available and affordable in low-resource countries.

Korea has achieved rapid growth in the fields of bioscience and biotechnology—with particular strengths regarding drug formulation development, vaccine manufacturing technology, and ICT combined diagnostics—which could have rapid and substantial positive impacts on patients in the developing world. We are confident that the application of Korea's technological strengths towards global health will improve worldwide healthcare access, which is essential in low-resource countries, representing a great step towards solving the problem of human health inequalities. The RIGHT Fund will play an important role in making this goal a reality.

In a major step forward, the RIGHT Fund was successfully launched in 2018, and made its first investments in 2019.

In 2020 and onward, the RIGHT Fund will increasingly focus on seeking investment opportunities with immediate impact, and identifying prospects for expanding Korea's contribution to solving global public health issues, which includes the introduction of the Technical Accelerator Award to support proof of concept of innovative research projects.

Keep an eye out for our future updates and developments!

CHAIRMAN OF THE BOARD
CHANGJIN MOON

CEO & EXECUTIVE DIRECTOR
YOUNBEEK KIM
INTRODUCTION

The RIGHT Fund, established in July of 2018 and based in Seoul, South Korea, is a research funding agency dedicated to supporting global health R&D through a three-way partnership between the Government of Korea (GOK), Korean life science companies, and international funders. The RIGHT Fund provides a platform for the GOK and Korean industry to increase their contributions to global health, and will serve as a vehicle for investment in R&D projects aimed at delivering tangible products to address disease burden in developing countries. The goal is to advance the discovery and development of new health technologies to meet the needs of low-income countries by leveraging the intellectual, technological, and financial resources of Korea.

Vision
To alleviate the burden of infectious disease that disproportionately affect the people in low-resource countries.

Mission
To mobilize Korea’s innovation and leadership to advance global health equity by promoting the discovery and development of new technologies that will meet the public health needs of developing countries.

**Funding Partners**

**International Funders**

*Bill & Melinda Gates Foundation*

+50 billion KRW
2018-2022 Funding

**Korean Companies**

*Full Partner*

LG Chem
SK bioscience
Genexine
Bioneer

*New Associate Partner*

SD BIOSENSOR
eubiologics

**Government of Korea**

Ministry of Health and Welfare

**Type of Award**

<table>
<thead>
<tr>
<th>Technical Accelerator Award (TAA)</th>
<th>Product Development Award (PDA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development Stage</td>
<td>Project Duration</td>
</tr>
<tr>
<td>Proof of Concept and Preclinical</td>
<td>Up to 12 months</td>
</tr>
<tr>
<td>Phase I and onward</td>
<td>Up to 36 months</td>
</tr>
<tr>
<td>Project Budget</td>
<td>Up to 500 million KRW</td>
</tr>
<tr>
<td>Up to 4 billion KRW</td>
<td></td>
</tr>
</tbody>
</table>

**Eligible Development Stages**

*Vaccine & Therapeutic*

Preclinical
Phase I
Phase II
Phase III
Registration

*Diagnostic & Digital Health*

Early Validation
Late Validation
Clinical Validation/Utility
Registration

**Investment Area**

Target Diseases
Infectious diseases endemic and emerging primarily in developing countries

**New Approaches & Constructs**

- **VACCINES**
  - New vaccines for target diseases
  - New pediatric combination vaccines
  - Improvements in immunization schedule, production method, thermostability, administration routes
  - Incrementally modified drugs
  - New treatment regimens and modifications that improve drug uptake and outcomes
  - Seeking or nearing WHO Prequalification
  - Lower-cost manufacturing platforms
- **THERAPEUTICS**
  - New chemical or biological approaches for currently unmet needs
  - New diagnostics and/or those that can improve efficiency of treatments
  - New low cost Point of Care tests
  - Seeking or nearing WHO Prequalification
  - Lower-cost diagnostic tools for use in low-resource settings
- **DIAGNOSTICS**
  - Improvements in existing diagnostics for use in low-resource countries
  - Improvements in existing digital health platforms for use in low-resource settings
- **DIGITAL HEALTH**
  - ICT applications for patient access tools or surveillance

**Product Improvements**

- **VACCINES**
  - Improvements in immunization schedule, production method, thermostability, administration routes
  - Incrementally modified drugs
  - New treatment regimens and modifications that improve drug uptake and outcomes
- **THERAPEUTICS**
  - Improvements in existing diagnostics for use in low-resource countries
  - Improvements in existing digital health platforms for use in low-resource settings
- **DIAGNOSTICS**
  - ICT applications for patient access tools or surveillance

**Patient Access**

- **VACCINES**
  - Improvements in immunization schedule, production method, thermostability, administration routes
  - Incrementally modified drugs
  - New treatment regimens and modifications that improve drug uptake and outcomes
- **THERAPEUTICS**
  - Improvements in existing diagnostics for use in low-resource countries
  - Improvements in existing digital health platforms for use in low-resource settings
- **DIAGNOSTICS**
  - ICT applications for patient access tools or surveillance

**Research Investment for Global Health Technology Fund**

2018-2022 Funding

International Funders

*Bill & Melinda Gates Foundation*

Korean Companies

*Full Partner*

LG Chem
SK bioscience
Genexine
Bioneer

*New Associate Partner*

SD BIOSENSOR
eubiologics

Government of Korea

Ministry of Health and Welfare

**Technical Accelerator Award Scope**

**Product Development Award Scope**
RIGHT Fund’s Public-Private Partnership

In-taek Lim  Director General for Health Industry of MOHW

“The RIGHT Fund represents a new and unique operating model of the Official Development Assistance (ODA) projects by fostering R&D capabilities of domestic life science companies beyond financial aid. A total of 50 billion Korean won has been raised through this public-private partnership for investments towards the development of the essential health technologies in developing countries. While efforts to overcome the current COVID-19 pandemic continue, it is equally important to establish a network of public-private collaborators to support R&D for infectious diseases in a more organized and sustainable way. The RIGHT Fund platform is well positioned and expected to be part of the Korean response to future epidemics.”

Andrin Oswald  former Director of Life Science Partnerships of BMGF

“Korea is an economic powerhouse and occupies an important position in global health, with its rapid innovations in the fields of bioscience and biotechnology. I believe that precisely understanding and promoting Korea’s strengths will accelerate changes in global health. Through the RIGHT Fund, the Gates Foundation wants to work strategically with the Korean government and key stakeholders, to more accurately identify Korea’s strengths that can affect global health, and thus promote changes. The application of Korea’s strengths in life science technology to meet the needs of developing countries will make a significant contribution to global public health. We hope that more Korean companies will work with the RIGHT Fund on R&D projects, which will ultimately have a positive impact on global health.”

Hun Kim  CTO of SK Bioscience

“The RIGHT Fund is an ODA platform that leads Korea’s contributions to global health by strengthening its R&D base. If the RIGHT Fund can accelerate the formation of a healthy ecosystem in the Korean biopharmaceutical industry, it could establish a strong foundation for our businesses in the future global health market. The RIGHT Fund can also support the growth of Korean technology companies on a global level, through collaboration with leading international organizations. Korean companies currently have strengths in late-stage development processes—such as in the development of low-cost manufacturing technology and formulation before commercialization—rather than in the early research stages. I hope that the RIGHT Fund can help to further build up the infrastructure of Korea’s technology strengths, thus improving its position in the global health market.”

Jeewoong Son  Executive Vice President of LG Chem

“LG Chem’s Life Science Business Division is making various efforts to contribute to global health by collaborating with other life science businesses, taking on the mission of ‘Science and Innovation to Save Life’. We hope to further develop the partnerships between various organizations for global health through the RIGHT Fund. Moreover, we hope that the pipeline of the projects supported by the RIGHT Fund will lead to the successful manufacture of products and substantial contributions to global health.”

Byung-Wha Kim  former Vice President of GC Pharma

“We anticipate that R&D partnerships with Korean companies, researchers, and overseas organizations will be further expanded through the RIGHT Fund, and will promote R&D for improved global health. Additionally, we hope that Korean companies will become more active in global public health R&D, and take action regarding concern for global health through the RIGHT Fund.”

Young-Joo Kim  President & CEO of Chong Kun Dang Pharm

“Healthcare services are not reliably provided to all of humanity worldwide, with particular deficits in developing countries. The key to improving global access to healthcare is the management of the costs and technologies associated with vaccines, therapeutics, and diagnostics. Solving these problems will require the cooperation of various organizations, including country governments and corporations. We are confident that the RIGHT Fund—a global public-private partnership that discovers and supports the technologies needed for developing countries by utilizing Korea’s innovation, leadership, and strengths—will contribute to the promotion of global public health. Furthermore, we expect that the RIGHT Fund could make significant strides in the development of innovative healthcare technology R&D.”

You Suk Suh  former CEO of Genexine

“Developing and disseminating good-quality vaccines in developing countries can be funding to perform the R&D if the profits of a product under development are not guaranteed. We hope that the RIGHT Fund, which pursues the public good based on its social mission, will bring more support from international organizations and governments, to create a force that drives the needed R&D, such as through copayment of development costs. Additionally, we hope that the RIGHT Fund will help Korean companies to do more R&D for global health.”
The RIGHT Fund’s investment portfolio consists of a total of 22 research and development (R&D) projects to date which were selected through three Request for Proposals (RFP).

From 2018 to the 1st half of 2020, two Product Development Award (PDA) RFPs and one Technical Accelerator Award (TAA) RFP were executed. The PDA is the standard award that supports mid-to-large scale development projects in pre-clinical stage onwards while the TAA supports development of early stage projects proof-of-concept. RIGHT Fund’s current portfolio includes research on COVID-19, cholera, tuberculosis, malaria, hepatitis A, meningococcal infection, leishmaniasis and typhoid fever.

The RIGHT Fund’s 1st PDA supports 5 R&D projects – 2 vaccines, 2 diagnostics, 1 therapeutic – while the 2nd PDA supports 5 R&D projects which include 4 vaccines and 1 diagnostic. The 1st TAA, launched in early 2020, supports a total of 12 projects, including 5 vaccines, 5 diagnostics and 2 digital health technologies.
**2019 PDA Projects**

**Novel Cholera Conjugate Vaccine**

- **euBiologics**
- **SK Bioscience**

Development of a single dose conjugate cholera vaccine (CCV) that bypasses the inherent limitations of immune response to the oral cholera vaccine (OCV) among children under 5 years in low-income country settings. The CCV is based on a novel conjugation technology developed at Massachusetts General Hospital and Harvard Medical School (MGH-Harvard) with pre-clinical animal proof-of-concept studies demonstrating protection in a neonatal marine challenge model.

**DTwP-HepB-IPV-Hib Hexavalent Vaccine**

- **LG Chem**

Combination vaccines provide many advantages including simplification of immunization schedules, fewer number of injections to infants and protection against multiple diseases. LG Chem's fully liquid DTwP-HepB-IPV-Hib vaccine candidate has completed Phase 2 clinical trials in healthy adults and is currently in Phase 2 with plans to enter Phase 3 clinical trials in early 2022.

**Continuous Manufacturing Process for New Antimalarial**

- **BioSquare**

DTwP-HepB-Hib Pentavalent MAP

- **LG Chem**

Development of a compartmental microneedle array patch (C-MAP) for delivering a pentavalent pediatric vaccine that protects against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib) leveraging QuadMedicine’s MMAP technology platform. The scope of work involves the formulation of each component, assessing immunogenicity, and the production of the MAP. This vaccine offers an effective alternative method in immunization programs with the possibility of overcoming the current limitations of vaccine formulation, delivery, storage and thermostability. Yonsei University will evaluate the immunogenicity of vaccination using C-MAP comparing the immune responses induced by intramuscular injection. LG Chem will manufacture and provide qualified antigen.

**2nd Generation G6PD Test**

- **SD BioSensor**

- **PATH**

- **Bioneer**

- **SD Biosensor** is currently working on a second-generation test with improvements that reduce false-positives and increase product shelf-life for better and effective use in remote settings. The updated components of the test will be evaluated by Program for Appropriate Technology in Health (PATH).

**POC for Multidrug-Resistant TB Test**

- **Bioneer**

- **FENDX**

- **DNDi**

Only 25% of patients with drug-resistant tuberculosis (DR-TB) globally are diagnosed and properly treated. Also currently available diagnostic tests of DR-TB offer only rifampicin detection. Bioneer aims to develop and validate a multidrug-resistant TB diagnostic test kit portable on a point-of-care (POC) test to measure G6PD deficiency prior to the administration of these drugs. SD BioSensor has already developed a first-generation quantitative point-of-care (POC) test to measure G6PD levels.

**Prime-Boost BCG Vaccine**

- **LG Chem**

- **SK Bioscience**

- **QuadMedicine**

- **LG Chem**

Prime-Boost BCG vaccine offers a strong product development and renowned cell culture expertise while Universcells has expertise in process design and development of low-footprint and low-cost vaccine manufacturing platform.

**Low-Cost HepA Vaccine Manufacturing Platform**

- **MicroMed**

- **Bioneer**

- **NPC**

- **Yonsei University**

Currently available Hepatitis A vaccines are expensive and under-supplied due to their challenging manufacturing process with slow kinetics and low yields. SK Bioscience aims to develop a cost-effective Hepatitis A vaccine on a small footprint, low-cost vaccine manufacturing platform in collaboration with Universcells. This HAV vaccine will be evaluated in pre-clinical studies for efficacy in relevant animal models, safety, and immunogenicity. Also, the manufacturing process of this vaccine will be integrated, chained and scaled into a low-footprint, micro-facility platform. SK Bioscience has strong product development and renowned cell culture expertise while Universcells has expertise in process design and development of low-footprint and low-cost vaccine manufacturing platforms.

**Quadrivalent Meningococcal Conjugate Vaccine**

- **euBiologics**

Currently available meningococcal conjugate vaccines have drawbacks such as narrow protection range, high prices, or inappropriate formulations like a lyophilized vaccine. EuBiologics is developing a quadrivalent meningococcal conjugate vaccine with serogroups of A, C, W-135, and Y conjugated to recombinant CRM197 in a liquid formulation.

**Leishmaniasis RDT Cartridge and Mobile Pocket Analyzer**

- **Bioneer**

- **Bioneer**

- **DNDi**

- **BioSquare**

Early detection and prompt treatment are critical in reducing the 70,000 estimated annual deaths from visceral leishmaniasis (VL). However, timely detection of VL is severely limited due to varying sensitivities and regional biases of currently existing point-of-care (POC) rapid diagnostic tests (RDTs). A more sensitive, non-biased diagnostic test would significantly improve current VL outcomes.

BioSquare is working with DNDi (Drugs for Neglected Diseases Initiative), CDT-Africa, OctiBio, and Institut Pasteur Korea to develop a POC RDT with high-temperature stability, high-sensitivity and accuracy that can detect human VL, with no cross reactivity, accompanied by a small mobile analyzer with wireless connectivity for use in low-resource settings. The scope of work includes device optimization and production of the antigen for VL.

**2020 PDA Projects**

**DTwP-HepB-Hib Pentavalent MAP**

- **LG Chem**

Development of a compartmental microneedle array patch (C-MAP) for delivering a pentavalent pediatric vaccine that protects against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib) leveraging QuadMedicine’s MMAP technology platform. The scope of work involves the formulation of each component, assessing immunogenicity, and the production of the MAP. This vaccine offers an effective alternative method in immunization programs with the possibility of overcoming the current limitations of vaccine formulation, delivery, storage and thermostability. Yonsei University will evaluate the immunogenicity of vaccination using C-MAP comparing the immune responses induced by intramuscular injection. LG Chem will manufacture and provide qualified antigen.
<table>
<thead>
<tr>
<th>PORTFOLIO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2020 TAA Projects</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>VACCINES AND THERAPEUTICS</strong></th>
<th><strong>DIAGNOSTICS AND DIGITAL HEALTH</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DISCOVERY</strong></td>
<td><strong>DISCOVERY</strong></td>
</tr>
<tr>
<td><strong>PRECLINICAL</strong></td>
<td><strong>EARLY VALIDATION</strong></td>
</tr>
<tr>
<td><strong>PHASE I</strong></td>
<td><strong>LATE VALIDATION</strong></td>
</tr>
<tr>
<td><strong>PHASE II</strong></td>
<td><strong>CLINICAL VALIDATION/UTILITY</strong></td>
</tr>
<tr>
<td><strong>PHASE III</strong></td>
<td><strong>REGISTRATION</strong></td>
</tr>
</tbody>
</table>

### VACCINES AND THERAPEUTICS

#### COVID-19 Vaccine Using Viral Vector System
- Development of a vaccine for COVID-19 using two different virus vectors. This project has the potential to develop a novel viral vector platform that can rapidly respond to future outbreaks. SK Bioscience will manufacture the recombinant viral vector expressing COVID-19 antigens and Catholic University of Korea will develop the animal model and evaluate its efficacy.

#### Microneedle-mediated SARS-CoV-2 DNA Vaccine
- Development of a COVID-19 Microneedle Array Patch (MAP) that can be used in low- and middle-income countries to administer DNA/RNA vaccines. It overcomes limitations with conventional electroporation methods to deliver nucleic acid vaccines. This project is led by QuadMedicine and Gachon University.

#### SARS-CoV-2 Nanogel Sublingual Vaccine
- Development of a nanogel adjuvant sublingual vaccine for SARS-CoV-2 by Konkuk Ctc bio Animal Vaccine (KCAV). Sublingual administration of vaccines can elicit immunity at mucosal sites and the nanogel carrier has applications to other recombinant viral vaccines.

#### Intransal Universal Respiratory Virus Vaccine
- A safety study of engineered long-acting IL-7 that enhances the T-cell immune response and provides protection in an influenza lethality model by Genexine. This vaccine reflects a pathogen agnostic approach and can be used in future outbreaks of viral respiratory infections.

#### Mpg Loaded TB Map Vaccine
- Development of a Mycobacterium paragordonae (Mpg) Microarray Patch tuberculosis (TB) vaccine with improved safety and efficacy over BCG by Raphas and Seoul National University. The project explores the potential of Mpg to replace BCG as a preventive and therapeutic vaccine.

### DIAGNOSTICS AND DIGITAL HEALTH

#### Instrument-Free Molecular Diagnostics Platform for COVID-19
- The R&D of an instrument-free, lateral flow molecular diagnostic platform for SARS-CoV-2 by Philmedi and Mmonitor. DNA manipulation is carried out on a single cartridge and quantified via smartphone. If successful, the project will help overcome current limitations of traditional PCR methods. It could expand the platform to other diseases for low-cost rapid diagnostic test (RDT).

#### Mobile Diagnostic platform for Influenza and SARS-CoV-2
- A test for flu and COVID-19 using lateral flow assay on a mobile phone platform by Precision Biosensor and Korea Basic Science Institute (KBSI). High-sensitive detection of multiple diseases is achieved through combined fluorescence and image analysis. This technology has potential application to other infectious diseases.

#### ICT Based Self-Risk Assessment Platform for COVID-19
- Development of a digital contact tracing mobile application that assesses the risk level of COVID-19 infection based on the individual's past route proximity to contaminated areas and symptoms by KT Corporation and Mobile Doctor. This technology will help individuals by guiding them to local public clinics to prevent further transmission and doctors determine the appropriate test and treatment options by triaging patients to use limited resources efficiently. This may also enhance the health authorities' epidemic investigation.

#### Quantitative POC Test Using mBFP
- Development of a quantitative, low-cost glucose-6-phosphate dehydrogenase (G6PD) point-of-care (POC) test using a proprietary blue fluorescent protein (mBFP) by Solgent that meets the needs of a low-cost G6PD test before malaria treatment. Validation of the test can expand mBFP technology to other diseases.

#### Rapid Diagnostic Test for Both S. Typhi and S. Paratyphi A
- Development of an immunochromatographic test for detection and differentiation of both Typhoid fever and Paratyphoid fever by ImmuneMed in collaboration with Child Health Research Foundation (CHRF) in Bangladesh. This project aims to distinguish serotypes S. Typhi and S. Paratyphi A. Differentiation of serotypes is important for epidemiological and antimicrobial resistance surveillance and monitoring to ensure the most effective treatment.
The RIGHT Fund’s first Investment Forum was held on July 17, 2019 in Seoul, Korea. At this forum, the RIGHT Fund announced the list of R&D projects selected through its first Request for Proposal (RFP) and the plan for its second RFP—thereby accelerating its role as a bridge leveraging Korea’s innovation and leadership and promoting partnerships with overseas R&D institutions for global public health.

An audience of about 100 members from Korean and non-Korean life science companies, research institutions, universities, international organizations, and nonprofit and nongovernmental organizations participated in the forum and the following partnering sessions. The RIGHT Fund Investment Forum comprised programs to promote partnerships in Korea and overseas, and to encourage deeper discussions of global health among the participants.

First, Katrine T. Andersen, Deputy Director, strategy planning and management for the Tuberculosis and Global Health Strategy of the Bill & Melinda Gates Foundation (BMGF), gave a lecture on “Strategic Collaborations for TB Control & Experience in Global Access.”
Presentations from MMV and DNDi highlighted the role of Product Development Partnerships (PDPs) and how these organizations work with funders, industry, and academic researchers to impact the lives of patients in low resource settings. The session also included an introductory presentation by Bryan Yeung, Senior Strategy Director of the RIGHT Fund, on the principles and investment priorities of the RIGHT Fund.

Chang-Jin Moon, Chairman of the Board of Directors of the RIGHT Fund, stated that “It is of great significance that different areas of health have joined forces to achieve the mission of promoting public health in developing countries. The RIGHT Fund Investment Forum is an event for those interested in our projects. I hope that we can have a meaningful footprint on this foundation.”

Younbeen Kim, CEO and Executive Director of the RIGHT Fund, also emphasized that “The RIGHT Fund intends to seek R&D projects that leverage Korean innovation and leadership to solve global health problems, and to promote partnership between Korean industry and foreign R&D institutes, and PDPs. We will continuously try to create more collaboration opportunities, through which we can further address the needs of developing countries.”

Next, Ajoy C. Chakrabarti, Portfolio & Platform Lead, Polio, Global Health Program of the BMGF, spoke on the subject of “Innovation in Vaccines and Biopharmaceuticals for Public Health”. Mae Shieh, Head of Business Development of the Drugs for Neglected Diseases initiative (DNDi), spoke on the “Role of Incremental Improvements in Global Health”. Finally, Joan Herbert, Senior Director of Business Development of the Medicines for Malaria Venture (MMV), delivered a lecture on “Powering Innovation Through Partnerships”. Topics discussed included current areas of focus in TB drug development, innovations in vaccine delivery and lower cost manufacturing platforms.
LEADERSHIP

The RIGHT Fund Leadership exerts to advance global health equity by promoting the discovery and development of technologies that will meet the public health needs of developing countries. The RIGHT Fund Leadership team consists of the Board of Directors, Council, Selection Committee, and Management Team. We perform collective and independent roles to come true to our goals.

Board of Directors

Chairman
Chang-Jin Moon
Younbeen Kim
In-tack Lim
Sungsoon Kim
Glenn Rockman
Kim Bush
Peter Hotez
Ex-Officio Observer

Council

Ministry of Health and Welfare
National Institute of Health
BILL & MELINDA GATES foundation
LG Chem
SK bioscience
GC Pharma
Genexine
International Vaccine Institute

Selection Committee

Chairman
Paul Herfing
Anni Mills-Duggan
Melissa Mathane
Insoo Kim
Christian Lienhardt
Gerald Voss
Joo Haeng Rhee
Dan Wattendorf

Management Team

Younbeen Kim
CEO & Executive Director
Bryan Young
Senior Director, Strategy
Jungjae Shim
Director/Operations
Kyungwoon Kim
Director/Comm.&PR
Young Shil Lim
Manager/Investment
Bora Yolee Kim
Associate/Investment
Yoonyoung Do
Officer/Operations
Kyounghee Song
Officer/Operations
**External Reviewers**

The RIGHT Fund's panel of External Reviewers is an expert advisory group consisting of domestic and international experts in the life sciences. They provide vital support that is critical to the work of the RIGHT Fund.

Abdelatif Elouahabi  |  Gerd Michel  |  Philip Hill
Ajit Pal Singh  |  Jelle Thole  |  Renaud Piarroux
Andreas Diacon  |  Jinho Hyeon  |  Robert Snow
Anita Suresh  |  Joel Leong  |  Taihwan Ha
Ann Ginsberg  |  John Donnelly  |  Thomas Keller
Anna Mandalakas  |  Junho Chung  |  Tom White
Bonnie Maldonado  |  Kamala Thriemer  |  Trevor Perrior
Christophe Bodenreider  |  Kysuk Yun  |  Woo Joo Kim
Daeseop Song  |  Laura Digilio  |  Wookyeong Seong
Dave Laffan  |  Leonard Sunwoo  |  Yeong Min Park
David Bell  |  Malcolm Duthie  |  Yeuchun Kim
Dominic Pucc  |  Marcel Tanner  |  Youngmee Jee
Fior Munoz  |  Marcel van Kasteel  |  Young June Choe
Gautam Sanyal  |  Michael Pollastri  |  Yuka Manabe
George Robertsoni  |  Nadia Tornieth  |  
Gerard Cunningham  |  Nicholas White  |  

---

**Special Thanks**

to All of Our Existing Partners

**Welcome**

to New Associate Partners
Location: SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, South Korea #08826
Contact us: +82-2-6337-9400
Write us: rightinfo@rightfund.org
Website: www.rightfund.org